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Cervical cancer (CC) is one of the most malignant tumors and the second or third most common type of cancer in
women worldwide. The association between human papillomavirus (HPV) and CC is widely known and accepted
(99.7% of cases). At present, the pathogenesis mechanisms of CC are not entirely clear. It has been shown that
inactivation of tumor suppressor genes and activation of oncogenes play a significant role in carcinogenesis, caused
by the genetic and epigenetic alterations. In the past, it was generally thought that genetic mutation was a key
event of tumor pathogenesis, especially somatic mutation of tumor suppressor genes. With deeper understanding
of tumors in recent years, increasing evidence has shown that epigenetic silencing of those genes, as a result of
aberrant hypermethylation of CpG islands in promoters and histone modification, is essential to carcinogenesis and
metastasis. The term epigenetics refers to heritable changes in gene expression caused by regulation mechanisms,
other than changes in DNA sequence. Specific epigenetic processes include DNA methylation, chromotin
remodeling, histone modification, and microRNA regulations. These alterations, in combination or individually, make
it possible to establish the methylation profiles, histone modification maps, and expression profiles characteristic of
this pathology, which become useful tools for screening, early detection, or prognostic markers in cervical cancer.
This paper reviews recent epigenetics research progress in the CC study, and tries to depict the relationships
between CC and DNA methylation, histone modification, as well as microRNA regulations.
Keywords: Cervical cancer, Human papillomavirus, Epigenetics alterations, BiomarkersReview
Cervical cancer
Cervical cancer (CC) is the second most prevalent neo-
plasia in women worldwide and the fifth cause of death
by cancer in this population, posing a significant public
health problem [1-3]. The incidence of CC and its pre-
cursor stages is high mainly in developing countries [4].
In 2008 an incidence of 15.8 and a mortality of 8.2 for
every 100,000 women was estimated. Around 529,000
new cases are detected every year, with nearly half of
these cases dying [5].
The pathogenesis of CC begins as a slow process that
interrupts the normal differentiation of the cervical
squamous epithelium, thereby producing changes in its
structure and physiology [6]. It initially presents through* Correspondence: jcroa@ufro.cl
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reproduction in any medium, provided the orprecursory lesions that evolve slowly and progressively,
which can then advance to slight, moderate, and severe
stages of dysplasia. CC may evolve into cancer in situ,
which is limited to the epithelial surface, and/or into inva-
sive cancer, in which case the involvement goes beyond
the basement membrane [7]. Therefore, one of the charac-
teristic factors of CC is its defined clinical stages, which
are associated with the different evolutionary stages that
lead to the development of the carcinogenesis [8].
It has been firmly established, both biologically and
epidemiologically, that the main cause of CC is due to a
persistent infection of high-risk human papillomavirus
(HPV) types, which are present in 99.7% of CC cases [9].
Nevertheless, the presence of a persistent high-risk HPV
infection risk is not sufficient to immortalize and trans-
form the epithelial cells of the host; it has been con-
firmed that the presence of genetic and epigenetic
alterations are needed for the development of carcino-
genesis. As a result, these factors taken together may
alter the control of the cell cycle, causing the host cell toal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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towards a malignant and invasive phenotype [10].
Human papillomavirus
HPV is a small, non-enveloped virus belonging to the
Papillomaviridae family of viruses [11]. It contains a circle
of double-stranded DNA approximately 8 kb in length
[9,12,13]. Generally, the HPV genome is composed of
three basic regions: an early region, composed of six open
reading frames (ORFs) known as E1, E2, E4, E5, E6, and
E7; a delayed region, with two coding ORFs for the struc-
tural viral proteins L1 and L2; and an upstream regulatory
region (URR) [14].
The HPV life cycle depends on the replication machinery
of the host cell and the differentiation of the squamous epi-
thelium of the cervix [9,15]. The cycle begins when infec-
tious viral particles arrive at the basal layer of the
epithelium, where they enter the host cell. In the cells of
the basal layer of the epithelium, the virus remains stable
within an episome with a low number of copies, making
up the virus reservoir [15,16]. Once the infected cells of
the basal layer are divided, some migrate towards the
superficial layer, lose their ability to divide, and initiate their
terminal differentiation, whereas the others remain in the
basal layer, self-renewing the population and maintaining
the infection. In the external layers of the epithelium, the
viral DNA is packed in capsids and the lineage is released
to initiate the infection again (Figure 1) [9,10,15,16].
During the progression of the carcinogenesis, the HPV
genome is integrated into the genome of the host cell, so
that the virus not only has a complete life cycle but also
manages to persist in the host cell. During this integra-
tion the coding regions for E1 and E2 are usually inter-
rupted, resulting in the loss of expression from the viral
E2 gene, which acts as a repressor of the gene expression
of E6 and E7, thus allowing an increase in the expression
of both proteins. The form by which E6 and E7 act
includes the inactivation of p53 and the hypophosphory-
lated retinoblastoma protein (pRB), two classic tumor
suppressor genes [17]. Currently it is known that E6 and
E7 are also linked to various proteins involved in the
processes of cell adhesion, including but not limited to
apoptosis, cell cycle, DNA repair, metabolism, transla-
tion, and transcription signals [6,12,14,17-19].
Epigenetics in CC
Epigenetics is defined as all those heritable changes in
gene expression that cannot be explained by an alter-
ation in the DNA nucleotide sequence [10]. The epigen-
etic modifications most studied are DNA methylation
and histone modification. Recently a new [10] epigenetic
phenomenon has been suggested, microRNA (miRNA),
which has been implicated in transcriptional silencing
[20,21].A series of epigenetic alterations have been identified
that occur during each of the stages of CC, both in the
HPV and in the genome of the host cell [10]. One of the
earliest pieces of evidence on record with respect to this
subject was thanks to a [3 H]-S-adenosylmethionine
incorporation assay performed on cervical neoplastic tis-
sue. In this study, it was observed that the degree of
hypomethylation (degree of incorporation of the [3 H]-
methyl group) increased progressively together with the
advance of the cervical neoplasia [22]. This finding was
confirmed by later studies that involved quantitative
analyses of DNA methylation supported by computer
analysis on interphase nuclei by immune-labeling
with anti-5-methylcytosine antibodies. A progressive
demethylation of the tissue was observed in samples of
dysplasia and cancer compared to normal controls
[23,24].
Indeed, most tumor suppressor genes possess pro-
moter regions rich in CpG islands, which tend to be
hypermethylated in CC, leading to the inactivity of these
genes [20].
Identification of numerous epigenetic alterations in all
cervical carcinogenesis stages reiterates the potential
value of methylation markers for improved diagnosis.
Twelve studies have been identified methylation mar-
kers in numerous specimens (serum/plasma, liquid-
based cytology, cytobrush samples, and urine) of cervical
cancer patients. The best performing panel of genes
(methylation status for four genes: CALCA, DAPK,
ESR1, and APC) was discovered by Wisman et al., in
cervical scrapings. Using this mathylation panel a sensi-
tivity of 89% and a specificity of 100% was achieved in
order to identify cervical cancer patients [25,26].
Methylation in CC
There are numerous reports demonstrating that abnor-
mal promoter hypermethylation leads to silencing or
diminished expression of tumor suppressor genes in cer-
vical carcinoma. Epigenetic silencing due to the methyla-
tion of genes involved in different regulatory pathways,
such as apoptosis, cell cycle control, and DNA repair,
among others, has been widely investigated. What
follows is a brief review of the genes described as methy-
lated in cervical carcinogenesis according to the pathway
involved [4].
Cell cycle
It is well established that cancer cells evolve as a result
of a deregulation in the normal cell cycle. The adequate
regulation of the cell cycle is essential for all cell types
and requires a great number of participant molecules,
such as cyclin-dependent kinases, along with other nat-
ural inhibitors like p16, Rb, and p15, which play an
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Figure 1 Progression of cervical cancer by HPV and promoter methylation during progression. Adapted from Woodman et al., 2007 [5].
The HPV virus has access to the basal cells by means of microlesions present in the cervical tissue. The virus is maintained in episomic form with
a low number of copies (cells with a purple nucleus). The cells of the basal layer are divided and begin to migrate towards the surface. The
untreated lesions progress to microinvasive and invasive cancer, where the HPV genome is associated with the host genome (cells with red
nuclei). In the superficial layer the viral DNA is packed in capsids and the progeny is released to reinitiate the infection.
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viral E6 and E7 oncogenes, which have the ability to
bind to the regulatory proteins of the host cell, particu-
larly to tumor suppressor genes like p53 and pRB. This
event might cause the degradation of p53 on the part of
E6 and the inactivation of pRB by binding it to E7 [28],
which in turn permits the overexpression of the cyclin-
dependent kinase inhibitor p16 (p16INK4A), leading to
genetic instability [29]. p16INK4A (MTS1, CDKN2)
encodes a nuclear phosphoprotein involved in the nega-
tive regulation of the cell cycle through the inhibition of
CDK4 or −6 by binding to the cyclin D1, which regulates
the G1 phase of the cell cycle. This mechanism enables
the deregulation of pRB1 at the checkpoint of the G1/S
phase, thereby affecting cell proliferation [29,30]. Ac-
cordingly, cases have been reported in which the
p16INK4A protein was found to be strongly expressed in
dysplasias and malignant cells of the squamous and
glandular epithelium of the cervix [31-33]. It is argued
that due to the action of the high-risk HPV viral onco-
gene E7 on the Rb protein, a negative feedback isproduced that leads to the overexpression of p16INK4A
[34,35]. However, the expression of p16INK4A in CC not
associated with infection by HPV might be explained by
independent pathways of the virus [33]. It has been
shown that the inactivation of the tumor suppressor
gene p16INK4A might be mediated by different genetic
and epigenetic mechanisms, the latter of which include
hypermethylation of the CpG islands in gene promoter
regions; nevertheless, this event is present only infre-
quently in cases of CC associated with infection by HPV.
In these reported cases, it has been observed that the de-
gree of methylation increases as the carcinogenesis pro-
gresses [10,30,33,36], being translated in the expression
silencing of p16INK4A. This in turn may provoke the
binding of the different CDKs involved in the cyclin D1
pathway, leading to the phosphorylation of Rb, this being
a key mechanism for releasing the cell cycle from con-
trol by Rb [14].
Cyclin A1 (CCNA1) is a cell cycle regulator essential at
the start of metaphase in male meiosis. Thus, a high
expression of CCNA1 has been found in testicular cells
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sion is low in many other types of cells [37,38]. Kitkum-
thorn et al. showed that the CCNA1 promoter region is
methylated in cases of CC, and the degree of methylation
advances as the oncogenesis progresses. Therefore, in nor-
mal samples and in low-grade lesions, no methylation was
found; whereas in high-grade lesions, microinvasive
cancer, and invasive cancer, 36.6%, 60%, and 93.3%,
respectively, were found.
DNA repair
Silencing of the DNA repair gene O6-methylguanine-DNA
methyltransferase (MGMT) by methylation of its promoter
region is an early event that occurs in various cancers.
This gene encodes a DNA repair protein that transfers
and accepts alkali groups from the O6 position of the
guanine, thereby preventing G>A mutations in the gen-
ome [39]. Iliopoulos et al. observed that methylation of
this gene increases progressively as the stages of CC ad-
vance [40]; similar results were obtained by Lin et al. [33].
In addition to being associated with control of the cell
cycle, the CCNA1 gene is also involved in the repair of
double-strand DNA breaks affected by radiation [41].
Hypermethylation of the CCNA1 promoter has been
associated with a loss of p53 function, which has gener-
ally been associated with a degradation resulting from
viral oncoprotein E6 [42].
Other genes less frequently related to DNA repair and
silenced by methylation of their promoter regions are
hMLH1 and FANC [10,43].
Cell differentiation and proliferation
The Wnt family of proteins involves a wide variety
of growth factors that regulate cell differentiation,
proliferation, migration, and oncogenesis during embry-
onic development [44]. It has been shown that the aber-
rant activation of the Wnt signaling pathway takes place
during carcinogenesis, inhibiting the apoptosis of tumor
cells in different human cancers. When Wnt ligands are
present, they bind to Frizzled (Fz) transmembrane
receptors, activating the dishevelled cytoplasmatic pro-
tein by phosphorylation. The activation of this protein
leads to the activation of the Wnt signaling cascade that
culminates in the accumulation of β-catenin in the cyto-
plasm. This is deposited in the nucleus, where it forms
complexes with members of the TCF/LEF cells and
increases the transcription of TCF/LEF-dependent target
genes, such as c-myc, cyclin D1, and TCF-1. In normal
conditions, that is, in the absence of the carcinogenic
process, the family of secreted frizzled-related proteins
(SFRPs) is the one responsible for antagonizing the Wnt
signaling pathway, among other antagonists. SFRPs bind
directly to the Wnt proteins and block their interaction
with the Fz transmembrane receptors. As the Wntsignaling pathway is blocked, the intracellular β-catenin
is phosphorylated, ubiquitinated, and finally degraded by
proteosomes. Thus, the absence in the nucleus of
β-catenin and TCF/LEF interaction might repress onco-
gene transcription [45-47]. It has been suggested that
the epigenetic silencing of antagonists of the Wnt
signaling pathway might result in the aberrant activation
of this pathway, leading to carcinogenesis.Apoptosis
The apoptosis pathway is interrupted in most human
cancers by various phenomena that affect the pathway’s
main components, as for example the suppression of
p14ARF, overexpression of MDM2, or mutation of p53
[48,49].
The p53 pathway responds to stress signals, as they
are the interruption in DNA replication fidelity and cell
division. These signals activate the p53 pathway specific-
ally by means of post-transcriptional modifications, en-
abling the arrest of the cell cycle, induction of
senescence or cell apoptosis [48,49]. One of the protein
layers to induce apoptosis is p73, a member of the p53
family of tumor suppressor proteins, a protein with both
a strong structural as well as functional homology.
This leads to this protein, when overexpressed, pos-
sibly activating the transcription of p53-responsive
genes, such as p21, Bax, MDM2, and GADD45, and to
cell growth inhibition by apoptosis induction [49,50].
P73 transcription is regulated by promoter regions and
the first exon of gene p73, regions rich in CpG dinucleo-
tides. Methylation in the cytokine residues of CpG dinu-
cleotides present in these regions plays a key role in the
regulation of p73 gene expression due to epigenetic
modifications. The transcriptional silencing of p73 has
been demonstrated in leukemia, lymphomas, brain
tumors, and ovary cell lines [51,52]. Recent studies have
reported the existence of epigenetic modifications that
might act on p73 through the hypermethylation of their
CpG islets, making it an important inactivation mechan-
ism of the gene expression of p73 in CC. In this study it
was observed that 38.8% of samples with CC presented
hypermethylation of the p73 gene vs. 3.2% in control
samples. The hypermethylation of p73 was significantly
related to the reduction or suppression of p73 expres-
sion. It is important to emphasize that the expression of
p73 is associated with favorable responses to radiation
therapy in CC, whereas suppression of the protein is
related to radioresistance [53].Histone modification
Cancer cells show histone modification patterns in indi-
vidual genes and generally at the nuclear level in
individual cells.
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(HDAC) are two enzymes with opposite activities,
responsible for regulating the transcriptional machinery,
controlling the state of histone acetylation. It has been
shown that these enzymes might be involved in cell prolif-
eration, cell differentiation, and regulation of the cell cycle
[54-56]. As a result, deregulation of the state of histone
acetylation at cell level might be related to the carcino-
genic process. In CC it has been shown that HDAC1 and
2 are overexpressed in cases of dysplasia and CC. The rela-
tion that presents the suppression of HDAC2 with the in-
crease of apoptosis, associated with an increase in the
p53-independent expression of p21Cip1/WAF1 was also
determined [54].
The MGMT gene, the participation of which in DNA
repair was detailed previously, is silenced in cases of CC
by histone deacetylase action [57]. It has also been
reported that the acetylated and phosphorylated forms
of histone H3 in cytological smears display a noticeable
association of histone H3 modification with the progres-
sion of carcinogenesis from low-grade to high-grade
lesions [58].
It has recently been demonstrated that the therapeutic
use of histone deacetylase inhibitors in CC has a high
anti-cancer potential [59].miR-16 Repression and subsequent normalization [61]
miR-27a Repression and subsequent normalization [61]
miR-142-5p Repression and subsequent normalization [61]
miR-21 Overexpressed [62]
miR-218 Repressed [63]miRNA
Several studies have proven the existence of miRNA
expression profiles in cervical cancer. Lee et al.
described the overexpression of 10 miRNA in CC: miR-
199-s, miR-9, miR-199a*, miR-199a, miR-199b, miR-145,
miR-133a, miR-133b, miR-214, and miR-127, and only
two repressed, miR-149 and miR-203 [60]. More recently
Pereira et al. demonstrated that a certain variability
exists with respect to the miRNA expression profiles;
they described eight miRNA that show a relative reduc-
tion in expression during the development of CC, from
normal tissue to atypical dysplasia and cancer: miR-26a,
miR-143, miR-145, miR-99a, miR-203, miR-513, miR-
29a, and miR-199a. Nevertheless, they described another
six miRNA that showed a drop in expression from the
transition from normal tissue to premalignant dysplasia,
but that returned to normal levels with the onset of can-
cer: miR-106a, miR-205, miR-197, miR-16, miR-27a, and
miR-142-5p [61].
miR-21 has been described as an oncogene in six types
of cancer; in CC it may promote cell proliferation and
might repress the expression of programmed cell death
4 (PCD4) [62]. The expression of miR-218 is reduced in
CC, its transcriptional target is laminin-5 β3 (LAMB3),
the expression of which increases in cases of CC, and
this has been reported as a marker of invasiveness in
cervical lesions (Table 1) [63].Thereby, the relationship between cervical carcinogen-
esis and epigenetics alterations like DNA methylation,
histone modifications, and miRNAs have received
increasing attention for their potential involvement in
the development of CC, especially its usefulness as bio-
markers of carcinogenesis. Epigenetic alterations can
serve as biomarkers in clinical studies and could be in
medical diagnostic. The reversible nature of epigenetic
alterations can be considered also for therapeutic
approaches of advanced stage cervical cancer.
Conclusions
In spite of being a relatively new area of study, epigen-
etic alterations have enabled the understanding of the
differences present in the gene expression profiles in dif-
ferent diseases, including carcinogenic processes. This
way, these alterations have become a powerful line of in-
vestigation for the establishment and progression of can-
cer. As far as CC is concerned, we can highlight the
ample number of genes affected by epigenetic alterations
at the level of gene methylation, histone modification,
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mation, valuable for the area of clinical diagnosis, has
made it possible to establish candidate genes that are
useful for the search of early detection biomarkers. Thus
the establishment of methylation profiles, histone modi-
fication maps, and miRNA expression profiles has be-
come the aim of many investigators, so as to be able to
propose new more sensitive and specific alternatives for
CC screening. In the same way, these epigenetic alter-
ation profiles could be used for the prognosis of the dis-
ease, for the assessment of the patient’s evolution prior
to the administration of a certain therapy and for its
implementation.
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